Superficial bladder tumors

European Urology

Volumn 42, Issue 6, 2002, Pages 533-541

  Chopin, Dominique K ^a   Gattegno, Bernard ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

Association Fran aise d'Urologie; Bladder instillations; Cystectomy; Superficial bladder cancer

Indexed keywords

BCG VACCINE; MITOMYCIN C;

BLADDER BIOPSY; BLADDER IRRITATION; BLADDER TUMOR; CANCER INVASION; CYSTECTOMY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ENDOSCOPIC SURGERY; HEMATURIA; HISTOPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURGICAL RISK; SURVIVAL; TREATMENT INDICATION; TUMOR GROWTH; TUMOR RECURRENCE; CANCER STAGING; CLASSIFICATION; HUMAN;

CYSTECTOMY; HUMANS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 0036901248     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00466-9     Document Type: Review

References (47)

1. Gattegno B, Chopin D. Tumeurs superficielles de la vessie. Prog Urol 2001;11:993.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827.
3. Bittard M. Association Française d'Urologie. 79th Session, Paris, 20-24 November 1985. J Urol 1985;91:647 [abstracts and reports].
4. Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: A systematic approach. Arch Environ Health 1991;46:6.
5. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. In: WHO, Geneva. Histological Typing of Tumours, vol. 10. Berlin: Springer; 1973.
6. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435.
7. Kurth K, Denis L, Sylvester R, et al. The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. Prog Clin Biol Res 1992;378:1.
8. Herr HW. Natural history of superficial bladder tumors: 10- To 20-year follow-up of treated patients. World J Urol 1997;15:84.
9. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499.
10. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Euro J Cancer 1994;11:1621.
11. Rischman P. Recommendations du comité de cancerologie de l'association française d'urologie. Tumeurs urothéliales. Prog Urol 1998;8(3(5)):25.
12. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998;16:17.
13. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388 [see comments].
14. Vallancien G, Veillon B, Charton M, et al. Can transabdominal ultrasonography of the bladder replace cystoscopy in the follow-up of superficial bladder tumors? J Urol 1986;136:32.
15. Boccon-Gibod L, le Portz B, Godefroy D, et al. Suprapubic ultrasonography in the follow-up of superficial bladder tumors. Eur Urol 1985;11:317.
16. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am 1992;19:455.
17. Meuleman EJ, Delaere KP. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma. Br J Urol 1988;62:150.
18. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review an meta-analyses. J Urol 2001;165(5):165 [abstract 680].
19. Van Der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages ta and t1 bladder tumors: A combined analysis of 5 European organization for research and treatment of cancer trials. J Urol 2000;164:1533.
20. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74.
21. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br J Urol 1994;73:164.
22. Hasui Y. Osada Y, Kitada S, et al. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994;43:782.
23. Schellhammer PF, Bean MA, Whitmore WF. Prostatic involvement by transitional cell carcinoma: Pathogenesis, patterns and prognosis J Urol 1977;118:399.
24. Lerner SP, Skinner DG, Lieskovský G, et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: Long-term results. J Urol 1993;149:758.
25. Hillyard Jr RW, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: Results of treatment with intravesical bacillus Calmette-Guerin. J Urol 1988;139:290.
26. Bretton PR, Herr HW, Whitmore WF, et al. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 1989;141:853.
27. Montie JE. High-stage bladder cancer: Bladder preservation or reconstruction? Cleve Clin J Med 1990;57:280.
28. Wishnow KI, Ro JY. Importance of early treatment of transitional cell carcinoma of prostatic ducts. Urology 1988;32:11.
29. Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998;16:1099.
30. Mishina T, Oda K, Murata S, et al. Mitomycin C bladder instillation therapy for bladder tumors. J Urol 1975;114:217.
31. Vegt PD, Debruyne FM, van der Meijden AP. Bacillus Calmette-Guerin in superficial bladder cancer: Consensus and controversies. Eur Urol 1995;27:89.
32. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998;159:783.
33. Lamm DL, Griffith JG. Intravesical therapy: Does it affect the natural history of superficial bladder cancer? Semin Urol 1992;10:39.
34. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: Results of a meta-analysis. Anticancer Res 2001;21:765.
35. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749.
36. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up. J Urol 1996;155:1233.
37. Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32:255.
38. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86.
39. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37:9.
40. Saint F, Patard JJ, Salomon L, et al. Mechanisms of action of BCG: Towards a new individualized therapeutic approach? Prog Urol 2000;10:1118.
41. Patard JJ, Saint F, Velotti F, et al. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: A review. Urol Res 1998;26:155.
42. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000;163:1124.
43. Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001;57:883.
44. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596.
45. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-Year outcome. J Urol 1997;158:62.
46. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296.
47. Pagano F, Fair WI, editors. Superficial Bladder Tumors. Oxford: ISIS; 1997.